申请人:Centrexion Therapeutics Corporation
公开号:US20170362249A1
公开(公告)日:2017-12-21
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.